Spevigo(spesolimab)
Spevigo (spesolimab) is an antibody pharmaceutical. Spesolimab was first approved as Spevigo on 2022-09-01. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Spevigo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Spesolimab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Spevigo | spesolimab-sbzo | Boehringer Ingelheim | N-761244 RX | 2022-09-01 | 3 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| spevigo | Biologic Licensing Application | 2025-06-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
spesolimab, Spevigo, Boehringer Ingelheim Pharmaceuticals, Inc. | |||
| 2029-09-01 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 6 | 2 | 1 | 2 | 12 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hidradenitis suppurativa | D017497 | — | L73.2 | — | 4 | 2 | — | — | 4 |
| Hidradenitis | D016575 | — | — | — | 4 | 2 | — | — | 4 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 4 | 1 | — | — | 4 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 4 | 1 | — | — | 4 |
| Ulcer | D014456 | MPATH_579 | — | — | 4 | 1 | — | — | 4 |
| Pyoderma gangrenosum | D017511 | EFO_0006835 | L88 | — | 1 | 1 | — | — | 2 |
| Pyoderma | D011711 | — | L08.0 | — | 1 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
| Netherton syndrome | D056770 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | — | 3 | — | — | — | 3 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 2 | — | — | — | 2 |
| Dermatitis | D003872 | — | L30.9 | — | 2 | — | — | — | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Spesolimab |
| INN | spesolimab |
| Description | Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL-36R) antagonist. It is given via injection into a vein.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 2097104-58-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297911 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15626 |
| UNII ID | 5IB2J79MCX (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 359 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
216 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use